What's breaking now, across thousands of outlets.
Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
The mangroves of Biscayne Bay have been getting help from an unlikely neighbor—the seagrass meadows just offshore. Dead seagrass blades and seaweed drift loose until the tide carries them into the…
About one-third of all drugs approved by the U.S. Food and Drug Administration target G protein-coupled receptors (GPCRs), a family of more than 800 cell-surface receptors that regulate a wide range…
As the Mediterranean Sea continues to warm, it may become more favorable for some tropical tuna species. However, warmer waters do not necessarily provide all the environmental conditions these highly…
The reversal marks a striking political U-turn from 2023, when the EU agreed to effectively end sales of new petrol and diesel cars by 2035.
Brussels says Montenegro is likely to become the EU's 28th member state, followed by Albania and Moldova. It said Ukraine needed to speed up reforms and offered fresh hope to Serbia following…
Brit Emma Walsley swaps big pharma for big printer: Prep for PCs, ink, and lots of DRAM-induced headaches
